Symbicort Turbohaler

DRUG3 trials

Sponsors

Mundipharma Research Limited, Orion Corporation, Orion Pharma, Pearl Therapeutics, Inc.

Conditions

AsthmaCOPD

Phase 1

Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers

CompletedNCT01668121

Orion Corporation, Orion PharmaAsthma

Start: 2012-08-31End: 2012-11-30Updated: 2012-11-27

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

CompletedNCT02189304

Pearl Therapeutics, Inc.COPD

Start: 2014-06-01End: 2014-09-01Updated: 2018-06-13

Phase 3

Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

CompletedNCT01099722

Mundipharma Research LimitedAsthma

Start: 2010-04-30End: 2011-07-31Updated: 2018-10-24

Related Papers

Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects.

2020-10-013 citations

Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults

Clinical Pharmacology in Drug Development2018-06-1416 citations